ERG and prostate cancer: In addition, depletion of HES5 in 5-aza-2′-deoxycytidine-treated prostate cancer cells (both ERG-positive and ERG-negative) will allow an assessment of de-repression of the endogenous HES5 locus on gene expression and cellular phenotypes.